

**Second Annual Conference
Of the Society for Adolescent and Young Adult Oncology:**



Breaking Barriers in Acute Lymphoblastic Leukemia

Irvine, California: October 6-8, 2014

SOCIETY FOR ADOLESCENT AND YOUNG ADULT ONCOLOGY		Monday, 6 October 2014
Three Age Groups: Childhood vs. AYA vs. Adult: What is Similar, What is Different		
13:00- 13:15 15 min	Leonard Sender, MD · UC Irvine CFCCC, CHOC Children's Hyundai Cancer Institute	
13:15-13:45 30 min	Mark Litzow, MD · Co-chair, Leukemia Committee, Eastern Cooperative Oncology Group (ECOG), Mayo Clinic	
Epidemiology		
13:45-14:25 40 min	Introduction to Acute Lymphoblastic Leukemia: Epidemiology of Childhood vs. Adolescent & Young Adult vs. Adult	
	Archie Bleyer MD · OHSU and St. Charles Health System	
	Julie Wolfson, MD · City of Hope National Medical Center	
Acute Lymphoblastic Leukemia Biology		
14:25-14:55 30 min	Genomic Alterations in ALL: Implications for Pathogenesis and Therapy	
	Charles Mullighan, MBBS(Hons), MSc, MD · St. Jude Children's Research Hospital	
14:55-15:25 30 min	Ikaros and Novel Approaches to Therapy of High-Risk B-ALL	
	Richard Van Etten MD, PhD · UC Irvine CHAO Family Comprehensive Cancer Center	
15 min	Q & A	
20 min	Break	
Pathology in Acute Lymphoblastic Leukemia		
16:00-16:10 10 min	Pathology Diagnostics: Is the Microscope Still Relevant?	
	Aaron Sassoon, MD, PhD · CHOC Children's Hospital/ St Joseph Hospital	
16:10-16:30 20 min	Classification of ALL: Is Cytogenetics Relevant in the Genomic Age?	
	Neda Zadeh, MD · CHOC Children's Hospital	
16:30-16:50 20 min	What's Next in Clinical Pathology: Virtual Pathology: GE-System Omnyx	
	Curtis Stratman MBA · GE Healthcare	
16:50-17:30 40 min	A strategic approach to discovery and clinical trials in the emerging era of targeted therapy: COG's Project: EveryChild	
	Peter Adamson, MD · Children's Oncology Group Chair	
The International Experience Part 1		
17:30-17:50 20 min	Italian and European ALL Experience	
	Andrea Biondi MD · "M.Tettamanti" Research Center H.S. Gerardo, Monza , Italy	
20 min	Q & A	
	Cheese & Wine	

Clinical: Leukemia Subtypes	
8:00-8:20 20 min	ALL Philadelphia Negative vs. Philadelphia Positive vs. Philadelphia-Like Deepa Jeyakumar MD · UC Irvine Chao Family Comprehensive Cancer Center
Leukemia Trials Clinical Update	
8:20-8:40 20 min	C10403 Clinical Trial Update Anjali Advani, MD · Cleveland Clinic
8:40-9:00 20 min	Lessons from Pediatric Leukemia Trial Stratification Stephen Hunger, MD · Univ. of Colorado School of Medicine
9:00-9:20 20 min	Treatment Protocol: Pediatrics vs. AYA vs. Adults; Clinical Trial vs. Treatment Plan Dan Douer MD · Memorial Sloane Kettering Cancer Center
9:20-9:40 20 min	Treatment of adults with acute lymphoblastic leukemia: Why do the specifics of the regimen matter? Adele Fielding, MB BS, PhD, FRCP, FRCPath · University College London
30 min	Q & A
20 min	BREAK
Next Generation Studies: Bring the Science to the Patient	
10:30-10:40 10 min	Children's Oncology Group Update Eric Larsen, MD
10:40-10:50 10 min	St. Jude Children's Research Hospital Sima Jema MD
10:50-11:00 10 min	Next Steps in Clinical Trials Dan DeAngelo MD · Dana Farber Cancer Institute
11:00-11:10 10 min	MD Anderson –HyperCVAD Regimen Update Elias Jabbour MD · MD Anderson Cancer Center
20 min	Q & A
90 min	LUNCH
Minimal Residue Disease	
13:00-13:25 25 min	Minimal Residual Disease: Overview, Flow Cytometry- COG Experience Stephen Hunger, MD · Univ. of Colorado School of Medicine
13:25-14:25 30 min* 30 min	Next Generation Sequencing: Sequenta ClonoSIGHT MRD Malek Faham, MD, PhD · Sequenta Aaron Logan MD, PhD · UCSF Helen Diller Family Comprehensive Cancer Center
14:25-14:50 25 min	Adaptive Technology- clonoSEQ™ David Wu, MD, PhD · University of Washington Harlan Robins PhD · Adaptive Biotechnologies, University of Washington
30 min	Q & A
40 min	BREAK

Tuesday, 7 October, 2014

Post-Induction Choices:	
16:00-16:30 30 min	After CR: Blood and Marrow Stem Cell Transplantation vs. Chemotherapy Approach Lloyd Damon, MD · UCSF Helen Diller Family Comprehensive Cancer Center
Chemotherapy Toxicity in Two Regimens: HyperCVAD vs. COG0232	
16:30-17:00 30 min	Adult: Regimen Related Toxicity Elias Jabbour MD · MD Anderson
17:00-17:30 30 min	Pediatric: Regimen Related Toxicity Eric Larsen, MD · Maine Children's Hospital
30 min	Q & A
FACULTY DINNER	



Wednesday, 8 October, 2014

SOCIETY FOR ADOLESCENT AND YOUNG ADULT ONCOLOGY	
8:00-8:30 30 min	Facilitating Allogeneic HCT for ALL: An Update from the National Marrow Donor Program Willis Navarro, MD · Atara, UCSF
Chemotherapy: The Role of Asparaginase	
8:30-10:20 90 min	Does Asparaginase Matter in Adult ALL, and How? Dan Douer, MD · Memorial Sloan Kettering Cancer Center
	Asparaginase toxicity –Overcoming Barriers Matthew Wieduwilt MD · UCSD Moores Cancer Center
	Asparaginase Experience in the UK: Lessons from 'UKALL14', a National study Adele Fielding, MB BS, PhD, FRCP, FRCPath · University College London
Immunotherapy	
10:20-11:20 60 min	Immunotherapy: CAR-T Cells Steven Grupp, MD, PhD · Children's Hospital of Philadelphia
11:20-11:50 30 min	BREAK
New Monoclonal Agents: Bridge to Transplant or Curative?	
11:50-12:10 20 min*	Blinatumumab –Biology Jonathan Benjamin MD, PhD · Medical Director, Global Development,, AMGEN
12:10-12:30 20 min	Blinatumumab- Clinical Anthony Stein MD · City of Hope Medical Center
12:30-12:50 20 min	Inotuzumab ozogamicin- Biology and Clinical Gary Schiller MD · UCLA
30 min	Q & A
60 min	LUNCH

Wednesday, 8 October, 2014

14:20-14:40 20 min	Chemobrain: A Novel Approach to Therapy Using qEEG-Guided Magnetic Resonance Therapy Kevin Murphy MD, PhD · UC San Diego Moores Cancer Center
14:40-15:00 20 min*	Next Generation Pathology Tim McDaniel, PhD · Translational Genomics Research Institute (TGen)
International Experience Part 2	
15:00-15:20 20 min	Australian ANZCHOG and AYA Leukemia Experience Antoinette Anazado MBBS, MRCPCH, MSC, FRACP · Sydney Children's Hospital and Prince of Wales Hospital, Australia
15:20-15:50 30 min	USA and UCSF Leukemia experience Lloyd Damon, MD · UCSF Medical Center
15:50-16:10 20 min	New Zealand Maori Leukemia Outcomes Tristan Pettit, MBChB FRACP · University of Otago, Christchurch, New Zealand
20 min	BREAK
Transplant	
16:30-17:10 20 min 20 min	Allogeneic: MRD vs. MUD vs. Haplo-identical Ralph Quinones, MD · University of Colorado School of Medicine Steven Neudorf, MD · CHOC Children's Hyundai Cancer Institute
17:10-17:30 20 min	Source of Cells: Cord vs. Peripheral Blood vs. Bone Marrow Joseph Rosenthal, MD · City of Hope National Medical Center
20 min	Q & A
Survivorship	
17:50-18:10 20 min	What is Specific about Survivorship in ALL Population; Lessons from CCSS Greg Armstrong, MD · St. Jude Children's Research Hospital
Summation	
18:10-18:30 20 min	Future Directions: Where do we go from here? Wendy Stock, MD · University of Chicago

The UC Irvine School of Medicine designates this live activity for a maximum of
21.25 AMA PRA Category 1 Credits™.

(*unaccredited session)

(rev 9/2014)